Skip to main content
. 2017 Jun 28;1:PO.16.00067. doi: 10.1200/PO.16.00067

Fig 4.

Fig 4.

Swimmer plots illustrating patients’ time on treatment of the therapy given immediately before molecular testing and time on treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor that was guided by molecular testing. Radiographic progression was the reason for treatment discontinuation in all cases.